What's New
Front Page
Tips & Advice: Finding Answers – FTD Research and You
When Damian McNamara, a staff writer for WebMD, learned that his cousin had been diagnosed with ALS…
Advancing Hope: AFTD Attends C9orf72 FTD/ALS Prevention Trial Workshop
A one-day C9orf72 FTD/ALS Prevention Trial Workshop was held in June 2024. The workshop was led by…
Care Partner Emphasizes the Benefits of Support from Others Who Understand FTD
Navigating the FTD journey is much less daunting when you have support from others who have lived…
Opinion Column Highlights Racial Disparities in Dementia Care and Need for Support
An opinion column published in the Los Angeles Daily News highlights healthcare-based racial disparities that often leave…
Volunteer Update: AFTD Welcomes New AFTD Ambassadors
Since the AFTD Ambassador Program began in 2019, our initial cohort of volunteer leaders has grown into an enthusiastic…
A Conversation with Olga Uspenskaya, MD, PhD, of Prevail Therapeutics
Recently, Prevail Therapeutics presented interim results from their Phase 1/2 open-label clinical trial assessing the safety and…
Passage Bio Receives Positive Feedback from FDA on Expanding Gene Therapy to C9orf72
Biopharmaceutical company Passage Bio announced on July 16 that it has received positive feedback from the U.S….
Researcher Explains the Role of Genetics in FTD, Discusses Avenues for Treatment
In an article written for The Conversation, Fen-Biao Gao, PhD, professor and founding director of the FTD…
British/Dutch Study Discovers Role of ANG Gene Mutations in ALS-FTD
Researchers at the University of Bath in the United Kingdom and the University Medical Center Utrecht in…